Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
INMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $12.72
Previous CloseN/A
Volume114.20K
Average Volume (3M)270.77K
Market Cap
$166.70M
Enterprise Value$83.51M
Total Cash (Recent Filing)$141.66K
Total Debt (Recent Filing)$350.00K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Apr 30, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding22,930,311
10 Day Avg. Volume299,981
30 Day Avg. Volume270,773
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4286.67
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.97K
Enterprise Value/Ebitda-2.73
Forecast
1Y Price Target
$23.33Price Target Upside219.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Inmune Bio News
PremiumCompany Announcements
INmune Bio’s Earnings Call: Key Insights and Future Prospects
PremiumCompany Announcements
INmune Bio Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
INmune Bio Reports Promising Phase I/II Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsINMB has implemented a patient enrichment strategy and utilizes a novel clinical endpoint, EMACC, to increase the likelihood of seeing a positive trial.
Market OpportunityRecessive dystrophic epidermolysis bullosa (RDEB) could represent a $1B opportunity with potential for premium pricing.
Regulatory ApprovalThe FDA has indicated during a Type C meeting that the data from the study could support a filing.
Bears Say
Financial PerformanceThe company ended the period with $20.9M in cash on the balance sheet, which excludes $5.4M raised via ATM; combined, this should provide runway into 2H25 and getting through two key catalysts.
Trial RisksThe large P2b trial testing Xpro in early Alzheimer's patients is expected to read out essentially all meaningful data within 100 days.
---
Ownership Overview
17.01% Insiders
4.02% Mutual Funds
6.29% Other Institutional Investors
67.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $4.32 and its highest was $12.72 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $166.70M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Apr 30, 2025 which is in 21 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Mar 27, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.548 by $0.148.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.48.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 22,930,311 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.548. Following the earnings report the stock price went up 1.484%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.33 (219.59% Upside)
$23.33 (219.59% Upside)
Blogger Sentiment
Neutral
INMB Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.40%
12-Months-Change
Fundamentals
Return on Equity
-119.83%
Trailing 12-Months
Asset Growth
-30.59%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
---
INMB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant upcoming milestones, such as the anticipated Phase 2 trial results for Alzheimer's and the BLA filing for the CORDStrom program. However, the increased net loss and high patient screening failure rate were notable challenges. Despite these challenges, the company's fundraising efforts have provided sufficient financial stability to continue operations.Read More>---
INMB Stock 12 Month Forecast
Average Price Target
$23.33
▲(219.59% Upside)
Technical Analysis
Cassava Sciences
―
Axon Enterprise
―
Aurinia Pharmaceuticals
―
Anavex Life Sciences
―
Annovis Bio
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
-7.84%
reiterated a buy rating 3 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -7.84% per trade.
---